5 Key Takeaways

• 1

  Elevated intraocular pressure (IOP) is the primary risk factor for glaucoma, and current therapies aim to manage it effectively.

• 2

  Surgical options for lowering IOP, such as trabeculectomy, are invasive and associated with high complication rates.

• 3

  Microinvasive glaucoma surgeries (MIGS) targeting the supraciliary space offer innovative drainage strategies with potentially fewer risks.

• 4

  The MINIject device, approved in Europe, shows promise in lowering IOP and is currently being evaluated in the U.S. through clinical trials.

• 5

  AlloFlo Uveo represents a hardware-free approach to enhance uveoscleral outflow, providing a bioconforming solution for glaucoma patients.